In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Targeted Cancer Therapeutics," features profiles of Coronado Biosciences, Emiliem and SynDevRx. Plus these Start-Ups Across Health Care: Activaero, Chakshu Research, Myomo and Valor Medical.

You may also be interested in...

Valor Medical Inc.

Valor Medical treats cerebral aneurysms with Neucrylate, which is injected through a microinfusion catheter introduced into the femoral artery of the leg, then passed up through the arterial system into the brain. Neucrylate is slowly delivered to the aneurysm in liquid form via a syringe. Once the product makes contact with blood, it immediately polymerizes into a soft, spongy solid to permanently relieve the blood pressure of the vessel wall of the aneurysm.

Emiliem Inc.

Virtual discovery company Emiliem is focused on kinase inhibitors for cancer. The company's K-STAR (Kinase Structure-Target Activity Relationship) platform incorporates new evidence from the scientific and patent literature into a model of kinase enzymes which play key roles in cell functions. Emiliem currently has candidates that target mTOR, Akt, and other kinase pathways; each drug candidate inhibits multiple kinases.

Activaero GMBH

Specializing in controlled breathing technologies for inhaled drug delivery Activaero GMBH is developing a suite of technologies that can efficiently deliver personalized dosing to different targets in the lungs. Activaero is seeking partners with dose-critical or expensive drugs that will benefit from the technology's dose-sparing benefits, or drugs that previously couldn't be delivered using the pulmonary route

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts